In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Wave Technologies Inc.

Division of Hologic Inc.
www.twt.com

Latest From Third Wave Technologies Inc.

People Briefs

Epigenomics, RainDance, and Brightree name new leadership, and more personnel news from around the industry.

Medical Device Regulation

Deals Of The Week: Sandoz/Fougera, Abbott/Action Pharma/Zealand, AstraZeneca/Axerion

New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.

BioPharmaceutical Deals

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2008

Highlights from the Q2 2008 review of device and diagnostics dealmaking: financing for medical device firms was down 9% from the first quarter to $838mm, which consisted mainly of late-stage venture rounds at 43% of the total. Big Pharma was surprisingly active in device acquisitions, with Novartis buying 25% of surgical instruments maker Alcon, and BMS selling off ConvaTec to private equity as part of its "string of pearls" strategy to focus on biotech. Two FOPOs dominated the $300mm financing the IVD/Research industry, while Invitrogen's $6.4bn stock swap for Applera's Applied Biosystems represented 90% of the M&A dollar volume.
Medical Device

C-Path Proposes NSCLC Initiative for EGFr Drugs and Diagnostics

In an encouraging sign for drug/diagnostic co-development, the independently funded C-Path Institute is now engaging more than 20 pharma and diagnostics companies with interests in non-small-cell lung cancer treatment using EGF receptor-targeted drugs and diagnostics. This proposed initiative could forge a template for future FDA reviews of drugs and companion diagnostics.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Hologic Inc.
  • Senior Management
  • Christopher Burton, SVP, Sales & Mktg.
    Jorge Garces, PhD, SVP, R&D
  • Contact Info
  • Third Wave Technologies Inc.
    Phone: (608) 273-8933
    502 South Rosa Rd.
    Madison, WI 53719-1256
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register